Abstract: A charging station monitoring system including: a sensing device, a digital camera and a communication device which are arranged at a charging apparatus of a charging station, the sensing device and the digital camera each having a sensing range covering a parking lot associated with the charging apparatus and an area around the parking lot; a controller configured to determine an occupation state of the parking lot and/or detect and record an action of a third party or foreign object based on sensed information from the sensing device and the digital camera; and a charging assistance device configured to recommend an environmentally friendly charging station if an energy storage device of the electric vehicle has not been fully charged and needs to be further charged.

Abstract: The present application provides a helper plasmid for preparing a recombinant adeno-associated virus (rAAV), including: 1) a coding sequence of an AAV Rep protein and a coding sequence of an AAV Cap protein; 2) at least one promoter sequence; and 3) at least one DA?sequence or AD? sequence, wherein the AD? sequence is a reverse complementary sequence of the DA? sequence. The present application also provides a method for increasing a production capacity of a rAAV using the helper plasmid. With an AD? sequence or a DA? sequence, the helper plasmid provided in the present application can significantly increase an AAV yield of a cell.

Abstract: Disclosed are a SARS-COV-2 antigen polypeptide, a recombinant adeno-associated virus (rAAV) expressing the polypeptide, and a vaccine containing the virus. A sequence of the antigen polypeptide is shown in SEQ NO. 1. and SEQ ID NO. 2. A method for preparing the recombinant adeno-associated virus comprises co-incubating pHelper, pRep2Cap5, and an expression vector, transfecting a cell in the presence of polyethyleneimine as a transfection reagent; culturing the cell, then collecting the cell by centrifugation, performing lysis and purification to obtain a purified liquid comprising the recombinant adeno-associated virus. The rAAV is delivered and expressed in vivo to produce a fusion antigen polypeptide, induces the production of serum neutralizing antibodies, which have a neutralizing titer to the novel SARS-COV-2 coronavirus and are expressed continuously; the rAAV composition can be used to immunize humans against the novel coronavirus pneumonia COVID-19.